Recent articles

The Breakthrough T1D International Board of Directors (IBOD) named two long-time volunteers to serve as Chair and Vice Chair when current board leaders end their two-year terms on July 1. Joseph P. Lacher, Jr., who is President and Chief Executive Officer of Kemper Corporation, will serve as Breakthrough T1D Chair, succeeding current Chair Ellen Leake. […]

Each year diabetes researchers from all over the world gather for the annual meeting of the Advanced Technologies & Treatments for Diabetes (ATTD), which this year took place on February 19-22 in Madrid, Spain. Many of the latest advances will be discussed, including research that Breakthrough T1D has funded to advance new breakthroughs and therapies […]

Breakthrough T1D is honored to recognize five leading international researchers whose work has and is transforming type 1 diabetes (T1D) science. We also are proud that our funding has helped drive their work forward toward both curing type 1 diabetes and improving the lives of those living with the disease today. The recipient of the […]

A new study commissioned by the Breakthrough T1D T1D Fund spotlights the high economic burden of type 1 diabetes (T1D) and the tremendous value of accelerating disease-modifying therapies. The study, released today, estimates the annual cost of T1D is more than $30 billion in the United States, where 1.6 million people are living with the […]

Universal screening for type 1 diabetes (T1D) is a priority for Breakthrough T1D, but the cost versus benefits remain unclear. Now, a large-scale population study in Bavaria, Germany, headed by Breakthrough T1D-funded Anette-Gabriele Ziegler, M.D., Ph.D., has a clue. The Fr1da study of nearly 100,000 children suggests that screening for autoantibodies—antibodies that are directed toward your […]

Press releases

Read the latest press releases and statements from Breakthrough T1D.

Get the latest in T1D news updates

Sign up for Insider News to receive breaking news updates from Breakthrough T1D.

  • This field is for validation purposes and should be left unchanged.